Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

…limited data from clinical studies in patients whose immune-related adverse reactions could not be controlled with corticosteroid use, administration of… clinical trials, visit http://ift.tt/1np5kw2. About Merck For 125 years, Merck has been a global health care leader working to help the world be…

mercknewsroom.com

Total Shares: 0

from Data Alerts http://ift.tt/2b0LXW1
via IFTTT